sodium phenylbutyrate and ursodoxicoltaurine


( Last Updated : November 25, 2021)
Generic Name:
sodium phenylbutyrate and ursodoxicoltaurine
Project Status:
Active
Therapeutic Area:
Amyotrophic lateral sclerosis (ALS)
Manufacturer:
Amylyx Canada
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0711-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
​​For the treatment of patients with amyotrophic lateral sclerosis (ALS).
Fee Schedule:
Pending
Indications:
​For the treatment of patients with amyotrophic lateral sclerosis (ALS).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones

Call for patient/clinician input open October 27, 2021
Call for patient/clinician input closed December 16, 2021
Submission received November 24, 2021
Submission accepted